The influence of CCPA and RF on the five-year outcomes in patients with early rheumatoid arthritisиве

Abstract

Objective: to study the influence of CCPA and RF on 5-year outcomes in patients with early rheumatoid arthritis (RA). Subjects and methods. 204 patients with early RA (0,05. Between RF (+) (n=138) and RF (-) (n=66) groups we did not find differences (p>0,05). Radiological damage in the CCPA(+) patients was more pronounced from the second year of the observation. Baseline, after 1 year SHS (M±o) was 19,7±10,5 (compared 15,1±8,9), 25,4±16,8 (20,3±12,2), p>0,05. From 2 to 5 years — 33,5±20,8 (25,3±14,2), 40,8±26,8 (31,9±20,2), 48,0±28,8 (37,2±22,6), 55,6±30,5 (44,0±24,5), respectively, p<0,05. This trend was determined in RF-positive patients. Conclusion. The CCPA- and RF-positive patients have the worst of 5-year radiological outcomes. CCPA-positive patients also have the worst clinical course during the first 4 years.

Keywords

• CCPA- and RF-positive patients
• genetically engineered biological agents
• rheumatoid artritis